<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153097</url>
  </required_header>
  <id_info>
    <org_study_id>ZYHX-001</org_study_id>
    <nct_id>NCT04153097</nct_id>
  </id_info>
  <brief_title>Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC</brief_title>
  <official_title>Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study is designed to assess the efficacy and safety of pembrolizumab for
      the treatment of Chinese advanced NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pembrolizumab is a humanized antibody used in cancer immunotherapy.The NMPA(China) approved
      pembrolizumab for first-line treatment of certain patients with advanced NSCLC.

      This is a multi-center non-interventional study, advanced NSCLC patients who treated with
      pembrolizumab and provide written informed consent will be included. The main objective of
      this study is to evaluate pembrolizumab efficacy and safety in the clinical practice and
      explore the prognosis-relevant factors of advanced NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Median Overall survival (OS) since start of pembrolizumab</measure>
    <time_frame>3 years</time_frame>
    <description>OS was defined as the length of time from the administration of the first-dose until death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) since start of pembrolizumab</measure>
    <time_frame>6 months</time_frame>
    <description>ORR was defined as the percentage of patients with complete response (CR) and partial response (PR) according to irRECIST.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Adverse Drug Reaction (ADR) since start of pembrolizumab</measure>
    <time_frame>up to 3 months after the last dose</time_frame>
    <description>Drug related AEs were evaluated using NCI-CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival (PFS) since start of pembrolizumab</measure>
    <time_frame>12 months</time_frame>
    <description>PFS is defined as the time from the start of first-dose to first progression disease (PD) or death, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time To Treatment failure (TTF) since start of pembrolizumab</measure>
    <time_frame>12 months</time_frame>
    <description>TTF is defined as the time from the start of first-dose to discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>pembrolizumab-treated advanced NSCLC</arm_group_label>
    <description>Patients with advanced non-small cell lung cancer treated with pembrolizumab</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Total 500 patients who receive pembrolizumab for advanced NSCLC will be enrolled. The
        patients should be registered consecutively in each site.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of advanced or metastatic NSCLC

          2. Patients who receive pembrolizumab for advanced NSCLC.

          3. Patients who provided written informed consent.

        Exclusion Criteria:

        1.Patients who would join any interventional clinical studies from first diagnosis to the
        end of the pembrolizumab treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianying Jianying, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianying Zhou, MD</last_name>
    <phone>13505719970</phone>
    <email>drzjy@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianya Zhou, MD</last_name>
    <phone>13858123060</phone>
    <email>zhoujianya@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianying Zhou, MD</last_name>
      <phone>13505719970</phone>
      <email>drzjy@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianya Zhou, MD</last_name>
      <phone>13858123060</phone>
      <email>zhoujianya@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital, Zhejiang University of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liren Ding, MD</last_name>
      <email>Lirending@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Hospital of Jiaxing</name>
      <address>
        <city>Jiaxing</city>
        <state>Zhejiang</state>
        <zip>314001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Lv, MD</last_name>
      <email>287473706@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinhua Guangfu Hospital</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <zip>321000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyu Wu, MD</last_name>
      <email>229901505@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Medical Center Lihuili Eastern Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaodong Tang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quzhou People's Hospital</name>
      <address>
        <city>Quzhou</city>
        <state>Zhejiang</state>
        <zip>324000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiqiang Han, MD</last_name>
      <email>hzq_qz@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuping Li, MD</last_name>
      <email>wzliyp@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Zhuji</name>
      <address>
        <city>Zhuji</city>
        <state>Zhejiang</state>
        <zip>310020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peifeng Chen, MD</last_name>
      <email>chenpeifeng2266@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 10, 2019</last_update_submitted>
  <last_update_submitted_qc>November 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share date of the trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

